# Marc Denis

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 152 papers | 5,605 citations | 100601 38 h-index | 107981 68 g-index |
| 159 all docs | 159 docs citations | 159 times ranked | 7583 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report. Translational Lung Cancer Research, 2022, 11, 100-110. | 1.3 | 6 |
| 2 | HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. Current Oncology, 2022, 29, 3748-3758. | 0.9 | 7 |
| 3 | Lung Cancer in France. Journal of Thoracic Oncology, 2021, 16, 21-29. | 0.5 | 13 |
| 4 | Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Translational Lung Cancer Research, 2021, 10, 1525-1535. | 1.3 | 11 |
| 5 | Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. Cancers, 2021, 13, 1826. | 1.7 | 9 |
| 6 | First-Line Afatinib plus Cetuximab for EGFR-Mutant Nonâ€“Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. Clinical Cancer Research, 2021, 27, 4168-4176. | 3.2 | 9 |
| 7 | MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer. Cancers, 2021, 13, 4203. | 1.7 | 3 |
| 8 | KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. Expert Opinion on Biological Therapy, 2021, 21, 1325-1334. | 1.4 | 4 |
| 9 | STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. Cells, 2021, 10, 3129. | 1.8 | 30 |
| 10 | Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clinical Lung Cancer, 2020, 21, e10-e14. | 1.1 | 18 |
| 11 | Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer, 2020, 140, 19-26. | 0.9 | 16 |
| 12 | Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients. Cancers, 2020, 12, 1871. | 1.7 | 14 |
| 13 | Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. Journal of Clinical Medicine, 2020, 9, 3861. | 1.0 | 23 |
| 14 | Predictive molecular pathology in nonâ€“small cell lung cancer in France: The past, the present and the perspectives. Cancer Cytopathology, 2020, 128, 601-610. | 1.4 | 13 |
| 15 | <p>Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic <em>EGFR</em>-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments</p>. Cancer Management and Research, 2020, Volume 12, 12593-12602. | 0.9 | 11 |
| 16 | Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. Journal of Thoracic Disease, 2020, 12, 2771-2780. | 0.6 | 13 |
| 17 | EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy. Expert Review of Anticancer Therapy, 2020, 20, 365-372. | 1.1 | 6 |
| 18 | Efficacy of imiquimod in the management of lentigo maligna.. Journal of Clinical Oncology, 2020, 38, 10074-10074. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Detection of ALK and ROS1 fusion transcripts in FFPE samples of non-small cell lung cancer patients using a novel RT-PCR based assay and targeted RNA sequencing.. Journal of Clinical Oncology, 2020, 38, e21695-e21695. | 0.8 | 0 |
| 20 | Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. PLoS ONE, 2019, 14, e0221123. | 1.1 | 14 |
| 21 | Use of circulating tumoral DNA to guide treatment for metastatic melanoma. Pharmacogenomics, 2019, 20, 1259-1270. | 0.6 | 6 |
| 22 | A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. Journal of Thoracic Oncology, 2019, 14, 903-913. | 0.5 | 132 |
| 23 | The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. OncoImmunology, 2019, 8, e1562834. | 2.1 | 7 |
| 24 | Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. Journal of Thoracic Disease, 2019, 11, S113-S126. | 0.6 | 45 |
| 25 | Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. Journal of Thoracic Disease, 2019, 11, 1370-1378. | 0.6 | 12 |
| 26 | Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 83. | 3.4 | 63 |
| 27 | Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).. Journal of Clinical Oncology, 2019, 37, 9079-9079. | 0.8 | 5 |
| 28 | PDâ€Ł1 expression by tumor cell lines: A predictive marker in melanoma. Experimental Dermatology, 2018, 27, 647-655. | 1.4 | 9 |
| 29 | <scp>BRAF</scp> mutations might be more common than supposed in vulvar melanomas. Experimental Dermatology, 2018, 27, 210-213. | 1.4 | 17 |
| 30 | Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. Clinical Chemistry, 2018, 64, 317-328. | 1.5 | 42 |
| 31 | Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget, 2018, 9, 25265-25276. | 0.8 | 46 |
| 32 | Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid. Lung Cancer, 2017, 114, 111-112. | 0.9 | 7 |
| 33 | Independent association of PDâ€Ł1 expression with noninactivated VHL clear cell renal cell carcinomaâ€"A finding with therapeutic potential. International Journal of Cancer, 2017, 140, 142-148. | 2.3 | 44 |
| 34 | Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients. Annales De Biologie Clinique, 2017, 75, 619-630. | 0.2 | 7 |
| 35 | Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. BMC Research Notes, 2017, 10, 320. | 0.6 | 7 |
| 36 | Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 12501-12516. | 0.8 | 112 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Clinical significance of <scp>BRAF</scp> mutation status in circulating tumor <scp>DNA</scp> of metastatic melanoma patients at baseline. Experimental Dermatology, 2016, 25, 783-788. | 1.4 | 34 |
| 38 | Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet, The, 2016, 387, 1415-1426. | 6.3 | 790 |
| 39 | Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation. Lung Cancer, 2016, 91, 73-74. | 0.9 | 28 |
| 40 | Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 61 | 0.8 | 17 |
| 41 | Cross-platform comparison of techniques to detect BRAF mutations in circulating tumor DNA of melanoma patients.. Journal of Clinical Oncology, 2016, 34, e21026-e21026. | 0.8 | 1 |
| 42 | EGFR mutation detection in plasma of lung tumor patients to predict success in treatment with tyrosine kinase inhibitors in a routine clinical setting.. Journal of Clinical Oncology, 2016, 34, e20545-e20545. | 0.8 | 0 |
| 43 | Activation of the prostaglandin D2 metabolic pathway in Crohnâ€™s disease: involvement of the enteric nervous system. BMC Gastroenterology, 2015, 15, 112. | 0.8 | 22 |
| 44 | Efficient Detection of BRAF Mutation in Plasma of Patients after Long-term Storage of Blood in Cell-Free DNA Blood Collection Tubes. Clinical Chemistry, 2015, 61, 886-888. | 1.5 | 26 |
| 45 | EGFR T790M resistance mutation in non small-cell lung carcinoma. Clinica Chimica Acta, 2015, 444, 81-85. | 0.5 | 61 |
| 46 | Effects of female increased body mass index on in vitro fertilization cycles outcome. Obesity Research and Clinical Practice, 2015, 9, 382-388. | 0.8 | 40 |
| 47 | Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 2015, 16, 1135-1148. | 0.6 | 26 |
| 48 | Comparative analysis ofBRAF,NRASandc-KITmutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma. Experimental Dermatology, 2015, 24, 70-73. | 1.4 | 5 |
| 49 | Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the CobasÂ® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, 2015, 10, e0120232. | 1.1 | 24 |
| 50 | Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. Oncology Reports, 2014, 32, 808-814. | 1.2 | 6 |
| 51 | Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?. Journal of Investigative Dermatology, 2014, 134, 1468-1470. | 0.3 | 37 |
| 52 | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival. Journal of Immunology Research, 2014, 2014, 1-10. | 0.9 | 25 |
| 53 | Efficiency of the TherascreenÂ® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clinica Chimica Acta, 2014, 429, 8-11. | 0.5 | 43 |
| 54 | A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Nonâ€“Small Cell Lung Cancer Settingâ€”IFCT/ERMETIC2 Project Part 1. Journal of Molecular Diagnostics, 2014, 16, 45-55. | 1.2 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?. Journal of Thoracic Oncology, 2014, 9, e49-e50. | 0.5 | 19 |
| 56 | BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity.. Journal of Clinical Oncology, 2014, 32, 9017-9017. | 0.8 | 0 |
| 57 | Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency.. Journal of Clinical Oncology, 2014, 32, 9069-9069. | 0.8 | 0 |
| 58 | Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. Journal of Neuro-Oncology, 2013, 114, 85-91. | 1.4 | 28 |
| 59 | New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Laboratory Investigation, 2013, 93, 1100-1114. | 1.7 | 36 |
| 60 | Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer, 2013, 82, 373-374. | 0.9 | 73 |
| 61 | Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472. | 1.1 | 11 |
| 62 | Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial. Blood Cancer Journal, 2013, 3, e154-e154. | 2.8 | 7 |
| 63 | Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples. International Journal of Oncology, 2013, 43, 1045-1051. | 1.4 | 32 |
| 64 | Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. PLoS ONE, 2013, 8, e68945. | 1.1 | 23 |
| 65 | Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 8000-8000. | 0.8 | 70 |
| 66 | Efficient detection of EGFR, KRAS, and BRAF mutations in cell-free DNA from pleural effusions.. Journal of Clinical Oncology, 2013, 31, e19151-e19151. | 0.8 | 0 |
| 67 | Detection of EGFR alterations in circulating cell-free DNA of lung tumor patients: Higher sensitivity obtained with plasma compared to serum.. Journal of Clinical Oncology, 2013, 31, e19046-e19046. | 0.8 | 0 |
| 68 | Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. International Journal of Oncology, 2012, 40, 2058-62. | 1.4 | 23 |
| 69 | Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 469-475. | 0.8 | 8 |
| 70 | Ovarian Reserve in Young Women of Reproductive Age with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2012, 18, 1515-1522. | 0.9 | 47 |
| 71 | Routine detection of EGFR gene mutations in lung carcinomas: A 2-year single-center experience.. Journal of Clinical Oncology, 2012, 30, e21117-e21117. | 0.8 | 0 |
| 72 | Relationship between IDH1 mutation status and magnetic resonance imaging features in WHO grade II and III oligodendroglial tumors.. Journal of Clinical Oncology, 2012, 30, 2082-2082. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | PPARÎ³ is functionally expressed in clear cell renal cell carcinoma. International Journal of Oncology, 2011, 38, 851-7. | 1.4 | 3 |
| 74 | Enteric glia modulate epithelial cell proliferation and differentiation through 15â€deoxyâ€Î”<sup>12,14</sup>â€prostaglandin J2. Journal of Physiology, 2010, 588, 2533-2544. | 1.3 | 81 |
| 75 | Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. Cancer Research, 2010, 70, 10329-10339. | 0.4 | 92 |
| 76 | Loss of expression of TIMP3 in clear cell renal cell carcinoma. European Journal of Cancer, 2010, 46, 1430-1437. | 1.3 | 44 |
| 77 | HtrA3 is regulated by 15-deoxy-Î”12,14-prostaglandin J2 independently of PPARÎ³ in clear cell renal cell carcinomas. Biochemical and Biophysical Research Communications, 2010, 394, 453-458. | 1.0 | 16 |
| 78 | KLF4â€dependent, PPARÎ³â€induced expression of GPA33 in colon cancer cell lines. International Journal of Cancer, 2009, 125, 2802-2809. | 2.3 | 62 |
| 79 | TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. International Journal of Molecular Medicine, 2009, 23, 41-8. | 1.8 | 32 |
| 80 | Experimental infection of specific pathogen-free pigs with Campylobacter: Excretion in faeces and transmission to non-inoculated pigs. Veterinary Microbiology, 2008, 131, 309-317. | 0.8 | 20 |
| 81 | Mucosal IL-10 and TGF-Î² play crucial roles in preventing LPS-driven, IFN-Î³â€“mediated epithelial damage in human colon explants. Journal of Clinical Investigation, 2008, 118, 1132-42. | 3.9 | 117 |
| 82 | Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncology Reports, 2007, 18, 1093. | 1.2 | 16 |
| 83 | Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor Î³, in colorectal adenocarcinoma. Oncology Reports, 2007, 18, 489. | 1.2 | 0 |
| 84 | Altered Calreticulin expression in human colon cancer: Maintenance of Calreticulin expression is associated with mucinous differentiation. Oncology Reports, 2007, 17, 1101-7. | 1.2 | 27 |
| 85 | Measurement of serum Anti-MÃ¼llerian Hormone by Beckman Coulter ELISA and DSL ELISA: Comparison and relevance in Assisted Reproduction Technology (ART). Clinica Chimica Acta, 2007, 375, 162-164. | 0.5 | 114 |
| 86 | Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RTâ€quantitative PCR in 94 breast cancer patients with a follow up of 9 years. Molecular Oncology, 2007, 1, 267-268. | 2.1 | 13 |
| 87 | Endogenous ILâ€10 prevents LPSâ€induced IFNgamma production in the human colonic mucosa. FASEB Journal, 2007, 21, A589. | 0.2 | 0 |
| 88 | Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor gamma, in colorectal adenocarcinoma. Oncology Reports, 2007, 18, 489-95. | 1.2 | 1 |
| 89 | Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncology Reports, 2007, 18, 1093-7. | 1.2 | 39 |
| 90 | ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease. Laboratory Investigation, 2006, 86, 1064-1073. | 1.7 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Human colonic myocytes are involved in postischemic inflammation through ADAM17-dependent TNFÎ± production. British Journal of Pharmacology, 2006, 147, 64-72. | 2.7 | 22 |
| 92 | Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. Journal of Pathology, 2005, 207, 156-163. | 2.1 | 121 |
| 93 | The PPARÎ³ K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Letters, 2005, 224, 111-116. | 3.2 | 7 |
| 94 | Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines. Anticancer Research, 2005, 25, 225-33. | 0.5 | 12 |
| 95 | Position in Cell Cycle Controls the Sensitivity of Colon Cancer Cells to Nitric Oxide-Dependent Programmed Cell Death. Cancer Research, 2004, 64, 4227-4234. | 0.4 | 54 |
| 96 | Loss of NOS1 expression in high-grade renal cell carcinoma associated with a shift of NO signalling. British Journal of Cancer, 2004, 90, 2364-2369. | 2.9 | 13 |
| 97 | Vasoactive intestinal peptide induces IL-8 production in human colonic epithelial cells via MAP kinase-dependent and PKA-independent pathways. Biochemical and Biophysical Research Communications, 2004, 317, 187-191. | 1.0 | 30 |
| 98 | Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Molecular and Cellular Probes, 2004, 18, 349-352. | 0.9 | 85 |
| 99 | Expression of NOS1 and soluble guanylyl cyclase by human kidney epithelial cells: Morphological evidence for an autocrine/paracrine action of nitric oxide. Kidney International, 2003, 64, 170-180. | 2.6 | 28 |
| 100 | Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. Digestive and Liver Disease, 2003, 35, 557-565. | 0.4 | 18 |
| 101 | Identification of secreted CD155 isoforms. Biochemical and Biophysical Research Communications, 2003, 309, 175-182. | 1.0 | 59 |
| 102 | Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. American Journal of Physiology - Renal Physiology, 2003, 285, G1028-G1036. | 1.6 | 151 |
| 103 | Sampling and the detection of melanoma cells in blood. Melanoma Research, 2002, 12, 291-292. | 0.6 | 5 |
| 104 | Growth phase-dependent expression of ICAD-L/DFF45 modulates the pattern of apoptosis in human colonic cancer cells. Cancer Research, 2002, 62, 2169-74. | 0.4 | 37 |
| 105 | Organization of the rat Tage4 gene and herpesvirus entry activity of the encoded protein. Gene, 2001, 265, 185-194. | 1.0 | 23 |
| 106 | Epitope mapping of four novel CD44 monoclonal antibodies using surface plasmon resonance and soluble CD44. Transfusion Medicine, 2001, 11, 447-454. | 0.5 | 3 |
| 107 | Overexpression of the CD155 gene in human colorectal carcinoma. Gut, 2001, 49, 236-240. | 6.1 | 233 |
| 108 | Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients. British Journal of Cancer, 2000, 82, 1283-1289. | 2.9 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clinical Cancer Research, 2000, 6, 3117-22. | 3.2 | 71 |
| 110 | Gene Walking by PCR Amplification of Short Fragments from Taq DNA Polymeraseâ€"Modified P1 Plasmid DNA and TA Cloning. BioTechniques, 1999, 27, 1118-1122. | 0.8 | 5 |
| 111 | Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. British Journal of Cancer, 1999, 80, 1995-2000. | 2.9 | 27 |
| 112 | Mapping of two different alpha-l,2-fucosyltransferase genes to rat Chromosome 1q22â€"q31. Mammalian Genome, 1997, 8, 297-298. | 1.0 | 4 |
| 113 | The Tage4 gene maps to rat Chromosome 1q22. Mammalian Genome, 1997, 8, 157-158. | 1.0 | 9 |
| 114 | Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients. , 1997, 74, 540-544. | | 116 |
| 115 | Circulating micrometastases following oncological surgery. Lancet, The, 1996, 347, 913. | 6.3 | 40 |
| 116 | Isolation and chromosomal location of mE4, a novel murine gene of the immunoglobulin superfamily. Mammalian Genome, 1996, 7, 636-637. | 1.0 | 19 |
| 117 | Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas. , 1996, 68, 817-821. | | 40 |
| 118 | Glycosylation of a novel member of the immunoglobulin gene superfamily expressed in rat carcinoma cell lines. International Journal of Cancer, 1995, 61, 87-91. | 2.3 | 5 |
| 119 | Qualitative low-level internal control for nested RT-PCR. BioTechniques, 1995, 19, 906-8. | 0.8 | 6 |
| 120 | H blood group antigen carried by CD44V modulates tumorigenicity of rat colon carcinoma cells. Cancer Research, 1994, 54, 6275-81. | 0.4 | 60 |
| 121 | A novel member of the immunoglobulin gene superfamily expressed in rat carcinoma cell lines. Journal of Biological Chemistry, 1994, 269, 15601-5. | 1.6 | 65 |
| 122 | Analysis of the relationship between stage of differentiation and nk/lak susceptibility of colon carcinoma cells. International Journal of Cancer, 1993, 53, 409-417. | 2.3 | 18 |
| 123 | Over-expression of the S13 ribosomal protein in actively growing cells. International Journal of Cancer, 1993, 55, 275-280. | 2.3 | 37 |
| 124 | Cloning and analysis of the human S13 ribosomal protein cDNA. Nucleic Acids Research, 1993, 21, 2945-2945. | 6.5 | 10 |
| 125 | Biological effects of glucocorticoid hormones on two rat colon adenocarcinoma cell lines. Journal of Steroid Biochemistry and Molecular Biology, 1992, 41, 739-745. | 1.2 | 11 |
| 126 | Isolation of cDNA clones corresponding to genes differentially expressed in two colon-carcinoma cell lines differing by their tumorigenicity. International Journal of Cancer, 1992, 50, 930-936. | 2.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Possible involvement of TGF beta 1 in the distinct tumorigenic properties of two rat colon carcinoma clones. Invasion & Metastasis, 1992, 12, 185-96. | 0.5 | 12 |
| 128 | Expression of alkaline phosphatase in murine lymphoma cells. Biochemical and Biophysical Research Communications, 1991, 177, 125-133. | 1.0 | 8 |
| 129 | Characterization, isolation and amino terminal sequencing of a rat colon carcinoma-associated antigen. International Journal of Cancer, 1991, 47, 903-908. | 2.3 | 18 |
| 130 | A secreted Mr â^¼ 40,000 glycoprotein specifically induced by glucocorticoids in a rat colon carcinoma cell line. International Journal of Cancer, 1991, 48, 774-778. | 2.3 | 3 |
| 131 | One-step 104-fold purification of transformed glucocorticoid receptor. Journal of Chromatography A, 1990, 508, 97-107. | 1.8 | 8 |
| 132 | Reaction of tyrosyl-modifying reagents with the ligand- and DNA-binding domains of the rabbit liver glucocorticoid receptor. The Journal of Steroid Biochemistry, 1990, 36, 15-23. | 1.3 | 3 |
| 133 | The transformed glucocorticoid receptor has a lower steroid-binding affinity than the nontransformed receptor. Biochemistry, 1990, 29, 1880-1886. | 1.2 | 101 |
| 134 | Glucocorticoid effects and receptors in two rat colon carcinoma cell lines differing by their tumorigenicity. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 223-230. | 1.2 | 11 |
| 135 | The specific DNA binding activity of the dioxin receptor is modulated by the 90 kd heat shock protein. EMBO Journal, 1990, 9, 69-76. | 3.5 | 61 |
| 136 | Immunocytochemical localization of glucocorticoid receptor in human gingival fibroblasts and evidence for a colocalization of glucocorticoid receptor with cytoplasmic microtubules. European Journal of Cell Biology, 1990, 53, 390-401. | 1.6 | 42 |
| 137 | Structure, function and regulation of the glucocorticoid receptor. Progress in Clinical and Biological Research, 1990, 322, 65-80. | 0.2 | 3 |
| 138 | Structural differences between the glucocorticoid, dioxin and oxysterol receptors from rat liver cytosol. Biochemical and Biophysical Research Communications, 1989, 163, 444-451. | 1.0 | 7 |
| 139 | The non-activated glucocorticoid receptor: Structure and activation. The Journal of Steroid Biochemistry, 1989, 34, 53-62. | 1.3 | 15 |
| 140 | Occurrence of glucocorticoid binding sites in solubilized microsomes from rat liver. The Journal of Steroid Biochemistry, 1989, 34, 325-330. | 1.3 | 8 |
| 141 | Ligand-dependent interaction of the dioxin receptor with target DNA. The Journal of Steroid Biochemistry, 1989, 34, 375-377. | 1.3 | 5 |
| 142 | Specific protein-DNA interactions at a xenobiotic-responsive element: copurification of dioxin receptor and DNA-binding activity.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 60-64. | 3.3 | 116 |
| 143 | The Association of the Glucocorticoid Receptor with Mr 90,000 Heat Shock Protein and Tubulin. , 1989, , 41-53. | | 0 |
| 144 | Translation of glucocorticoid receptor mRNA in vitro yields a nonactivated protein. Journal of Biological Chemistry, 1989, 264, 6005-8. | 1.6 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Two-step purification and N-terminal amino acid sequence analysis of the rat Mr 90,000 heat shock protein. Analytical Biochemistry, 1988, 173, 405-411. | 1.1 | 32 |
| 146 | Requirement of hormone for thermal conversion of the glucocorticoid receptor to a DNA-binding state. Nature, 1988, 333, 686-688. | 13.7 | 195 |
| 147 | Subunit composition of the molybdate-stabilized non-activated glucocorticoid receptor from rat liver. The Journal of Steroid Biochemistry, 1988, 30, 271-276. | 1.3 | 15 |
| 148 | Application of high-performance ion-exchange chromatography to the analysis of cytosolic glucocorticoid receptor. The Journal of Steroid Biochemistry, 1988, 30, 281-285. | 1.3 | 11 |
| 149 | Association of the dioxin receptor with the Mr 90,000 heat shock protein: A structural kinship with the glucocorticoid receptor. Biochemical and Biophysical Research Communications, 1988, 155, 801-807. | 1.0 | 229 |
| 150 | Interaction of the glucocorticoid receptor with the Mr â‰ˆ 90 000 heat shock protein. Biochemical Society Transactions, 1988, 16, 688-690. | 1.6 | 9 |
| 151 | Interaction of the Mr = 90,000 heat shock protein with the steroid-binding domain of the glucocorticoid receptor. Journal of Biological Chemistry, 1988, 263, 18520-3. | 1.6 | 86 |
| 152 | Nontransformed rabbit liver glucocorticoid receptor: purification, characterization and transformation. Biochimie, 1985, 67, 1267-1278. | 1.3 | 11 |